The PPG titled Frontotemporal Dementia: Genes, Images and Emotions? has four Projects and five Cores. Project 3 probes socioemotional function to find optimal predictors using, multi-method laboratory and home assessments to separate frontotemporal dementia (FTD), Alzheimer's disease (AD), and mood disorders (MD), and to define brain regions that underlie emotion. Project 4 aims to improve diagnosis of behavioral variant FTD (bvFTD) versus AD, major depressive disorder (MDD), and bipolar disorder (BD) while studying the value of clinical, imaging, and other biomarker techniques to diagnose the different molecular causes for bvFTD. Project 6 uses novel models of network-based prediction grounded in task-free fMRI (tf-fMRI) to predict atrophy, the spread of atrophy, and progression of the tau PET signal in patients with suspected FTLD with tau, to elucidate disease mechanisms and refine methodology for research and treatment trials. Project 7 studies the language and non-language features of the 3 PPA subtypes svPPA, nfvPPA and logopenic variant PPA and will determine their longitudinal progression and improve their molecular diagnosis. Core A (Administrative and Clinical Core) evaluates PPG patients and collects clinical and biomarker measures. A new group with MDD and BD will be studied with the same measures used in FTD and AD. Core B (Neuropathology Core) will define FTLD, AD, and other pathology in our autopsied patients, while serving as a gold standard for diagnosis in all PPG projects. It will supply samples to basic scientists. Core C (Data Management and Biostatistics Core) will manage and facilitate visualization of PPG data and will offer biostatistical consultation across the cores. Core D (Genetics Core) will determine genetic mutations and risk genes in the PPG cohort and explore the role of whole exome and whole genome analyses and gene expression profiles to predict FTLD and AD subtypes. Core E (Imaging Core) will acquire and analyze MRI and PET images for research studies 3,4,6, and 7 and will use PET combined (amyloid [PIB] and tau [AV1451]) to detect and stage AD pathology and to explore the utility of AV1451 for detecting and tracking tau pathology in FTD.

Public Health Relevance

OVERALL NARRATIVE The FTD PPG will benefit public health through advancing knowledge of clinical diagnostic processes, genomic, basic, translational, and clinicopathological research regarding prevalent neurodegenerative diseases and common mood disorders of aging.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG019724-16
Application #
9280089
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (J1))
Program Officer
Hsiao, John
Project Start
2002-04-01
Project End
2022-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
16
Fiscal Year
2017
Total Cost
$1,967,009
Indirect Cost
$529,469
Name
University of California San Francisco
Department
Neurology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Miller, Zachary A; Rosenberg, Lynne; Santos-Santos, Miguel A et al. (2018) Prevalence of Mathematical and Visuospatial Learning Disabilities in Patients With Posterior Cortical Atrophy. JAMA Neurol 75:728-737
Rojas, Julio C; Stephens, Melanie L; Rabinovici, Gil D et al. (2018) Multiproteinopathy, neurodegeneration and old age: a case study. Neurocase 24:1-6
Dijkstra, Anke A; Lin, Li-Chun; Nana, Alissa L et al. (2018) Von Economo Neurons and Fork Cells: A Neurochemical Signature Linked to Monoaminergic Function. Cereb Cortex 28:131-144
Mok, Sue-Ann; Condello, Carlo; Freilich, Rebecca et al. (2018) Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol 25:384-393
Erkkinen, Michael G; Zúñiga, Raquel Gutiérrez; Pardo, Cristóbal Carnero et al. (2018) Artistic Renaissance in Frontotemporal Dementia. JAMA 319:1304-1306
Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858
Ljubenkov, Peter A; Staffaroni, Adam M; Rojas, Julio C et al. (2018) Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol 5:1250-1263
La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290
Kim, Eun-Joo; Brown, Jesse A; Deng, Jersey et al. (2018) Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series. J Neurol 265:2960-2971
Henry, Maya L; Hubbard, H Isabel; Grasso, Stephanie M et al. (2018) Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain 141:1799-1814

Showing the most recent 10 out of 607 publications